Pharmaceutical product list
Currently, the KD Pharma Group has 3 pharmaceutical drugs in the final stages of development in the US and EU. These new IP protected formulas address the cardiovascular and selected oncology sectors. The KD Pharma Group is also looking for Licensing Partners in various countries for these products. For more information please contact us at: pharma@kdpharmagroup.com
The KD Pharma Group is the only Omega-3 drug producer that has the full spectrum of separation technologies available on an industrial scale. These include distillation, HPE, SFE, SFC, Urea, Ag-extraction and others. This allows the KD Pharma Group to produce any fatty acid composition for the development and commercialization of new Omega-3 based pharmaceuticals. The majority of all new Omega-3 drug developments receive their API from the KD Pharma Group.
Active Pharmaceutical Ingredients (API)
-
465375EE (USP) bulk oil
API for generic LOVAZA in the US and generic LOTRIGA in Japan -
460380EE (EP) bulk oil
API for generic OMACOR in EU and South Korea -
550200FFA (USP) bulk oil
API for generic EPANOVA in the US
Various: We can produce your specific Omega-3 API under full cGMP conditions.
KD Pharma's Approved Pharmaceutical Ingredients (APIs, mg/g)
KD-Pür® (mg/g) Pharmaceuticals
PRODUCT | EPA | DHA | EPA + DHA | OMEGA-3 FATTY ACIDS |
460380EE (EP) Generic Omacor | NLT 40% | NLT 34% | NLT 80% | NLT 90% |
465375EE (USP) Generic Lovaza | 430-495 | 347-403 | 800-880 | NLT 90% |
550200FFA Generic Epanova | 500-600 | 150-250 | not defined | not defined |